Untapped potential of gut microbiome for hypertension management

References

• Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP. et al. Global burden of cardiovascular diseases and risk factors, 1990–2019. J Am Coll Cardiol. 2020;76(25):2982–17. doi:10.1016/j.jacc.2020.11.010.
   PubMed Web of Science ®Google Scholar
• Mahase EH. Hypertension: 76 million deaths could be averted by 2050 if treatment coverage improves, says WHO. BMJ. 2023;382:2154. doi:10.1136/bmj.p2154.
   PubMedGoogle Scholar
• Yang BY, Qian Z, Howard SW, Vaughn MG, Fan SJ, Liu KK, Dong GH. Global association between ambient air pollution and blood pressure: A systematic review and meta-analysis. Environ Pollut. 2018;235:576–588. doi:10.1016/j.envpol.2018.01.001.
   PubMed Web of Science ®Google Scholar
• Park S, Kario K, Chia YC, Turana Y, Chen CH, Buranakitjaroen P, Nailes J, Hoshide S, Siddique S, Sison J. et al. The influence of the ambient temperature on blood pressure and how it will affect the epidemiology of hypertension in Asia. J Clin Hypertens. 2020;22(3):438–444. doi:10.1111/jch.13762.
   Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A. et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of cardiology and the European society of hypertension: the task force for the management of arterial hypertension of the European society of cardiology and the European society of hypertension. J Hypertens. 2018;36:1953–2041. doi:10.1097/HJH.0000000000001940.
   PubMed Web of Science ®Google Scholar
• Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, Zhu D, Koya JB, Wei L, Li J. et al. Microbiota in health and diseases. Signal Transduct Target Ther. 2022;7(1):135. doi:10.1038/s41392-022-00974-4.
   PubMed Web of Science ®Google Scholar
• Donaldson GP, Lee SM, Mazmanian SK. Gut biogeography of the bacterial microbiota. Nat Rev Microbiol. 2016;14(1):20–32. doi:10.1038/nrmicro3552.
   PubMed Web of Science ®Google Scholar
• Guarner F, Malagelada JR. Gut flora in health and disease. Lancet. 2003;361(9356):512–519. doi:10.1016/S0140-6736(03)12489-0.
   PubMed Web of Science ®Google Scholar
• Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, Gordon JI, Relman DA, Fraser-Liggett CM, Nelson KE. Metagenomic analysis of the human distal gut microbiome. Science. 2006;312(5778):1355–1359. doi:10.1126/science.1124234.
   PubMed Web of Science ®Google Scholar
• Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, Pettersson S. Host-gut microbiota metabolic interactions. Science. 2012;336(6086):1262–1267. doi:10.1126/science.1223813.
   PubMed Web of Science ®Google Scholar
• Björkstén B, Sepp E, Julge K, Voor T, Mikelsaar M. Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol. 2001;108(4):516–520. doi:10.1067/mai.2001.118130.
   PubMed Web of Science ®Google Scholar
• Mariat D, Firmesse O, Levenez F, Guimarăes V, Sokol H, Doré J, Corthier G, Furet JP. The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol. 2009;9:123. doi:10.1186/1471-2180-9-123.
   PubMed Web of Science ®Google Scholar
• Yan Q, Gu Y, Li X, Yang W, Jia L, Chen C, Han X, Huang Y, Zhao L, Li P. et al. Alterations of the gut microbiome in hypertension. Front Cell Infect Microbiol. 2017;7:381. doi:10.3389/fcimb.2017.00381.
   PubMed Web of Science ®Google Scholar
• Li J, Zhao F, Wang Y, Chen J, Tao J, Tian G, Wu S, Liu W, Cui Q, Geng B. et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome. 2017;5(1):14. doi:10.1186/s40168-016-0222-x.
   PubMed Web of Science ®Google Scholar
• Dinakis E, Nakai M, Gill P, Ribeiro R, Yiallourou S, Sata Y, Muir J, Carrington M, Head GA, Kaye DM. et al. Association between the gut microbiome and their metabolites with human blood pressure variability. Hypertension. 2022;79(8):1690–1701. doi:10.1161/HYPERTENSIONAHA.122.19350.
   PubMed Web of Science ®Google Scholar
• Virwani PD, Qian G, Hsu MSS, Pijarnvanit TKKT, Cheung CN, Chow YH, Tang LK, Tse YH, Xian JW, Lam SS. et al. Sex differences in association between gut microbiome and essential hypertension based on ambulatory blood pressure monitoring. Hypertension. 2023;80(6):1331–1342. doi:10.1161/HYPERTENSIONAHA.122.20752.
   PubMed Web of Science ®Google Scholar
• Yang Z, Wang Q, Liu Y, Wang L, Ge Z, Li Z, Feng S, Wu C. Gut microbiota and hypertension: association, mechanisms and treatment. Clin Exp Hypertens. 2023;45(1):2195135. doi:10.1080/10641963.2023.2195135.
   PubMed Web of Science ®Google Scholar
• Kaye DM, Shihata WA, Jama HA, Tsyganov K, Ziemann M, Kiriazis H, Horlock D, Vijay A, Giam B, Vinh A. et al. Deficiency of prebiotic fiber and insufficient signaling through gut metabolite-sensing receptors leads to cardiovascular disease. Circulation. 2020;141(17):1393–1403. doi:10.1161/CIRCULATIONAHA.119.043081.
   PubMed Web of Science ®Google Scholar
• Pluznick JL, Protzko RJ, Gevorgyan H, Peterlin Z, Sipos A, Han J, Brunet I, Wan LX, Rey F, Wang T. et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci USA. 2013;110(11):4410–4415. doi:10.1073/pnas.1215927110.
   PubMed Web of Science ®Google Scholar
• Onyszkiewicz M, Gawrys-Kopczynska M, Konopelski P, Aleksandrowicz M, Sawicka A, Koźniewska E, Samborowska E, Ufnal M. Butyric acid, a gut bacteria metabolite, lowers arterial blood pressure via colon-vagus nerve signaling and GPR41/43 receptors. Pflugers Arch Eur J Physiol. 2019;471(11–12):1441–1453. doi:10.1007/s00424-019-02322-y.
   PubMed Web of Science ®Google Scholar
• Bartolomaeus H, Balogh A, Yakoub M, Homann S, Markó L, Höges S, Tsvetkov D, Krannich A, Wundersitz S, Avery EG. et al. Short-chain fatty acid propionate protects from hypertensive cardiovascular damage. Circulation. 2019;139(11):1407–1421. doi:10.1161/CIRCULATIONAHA.118.036652.
   PubMed Web of Science ®Google Scholar
• Kim S, Goel R, Kumar A, Qi Y, Lobaton G, Hosaka K, Mohammed M, Handberg EM, Richards EM, Pepine CJ. et al. Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure. Clin Sci (Lond). 2018;132(6):701–718. doi:10.1042/CS20180087.
   PubMed Web of Science ®Google Scholar
• Ufnal M, Jazwiec R, Dadlez M, Drapala A, Sikora M, Skrzypecki J. Trimethylamine-N-oxide: a carnitine-derived metabolite that prolongs the hypertensive effect of angiotensin II in rats. Can J Cardiol. 2014;30(12):1700–1705. doi:10.1016/j.cjca.2014.09.010.
   PubMed Web of Science ®Google Scholar
• Chen H, Li J, Li N, Liu H, Tang J. Increased circulating trimethylamine N-oxide plays a contributory role in the development of endothelial dysfunction and hypertension in the RUPP rat model of preeclampsia. Hypertens Pregnancy. 2019;38(2):96–104. doi:10.1080/10641955.2019.1584630.
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Lulla A, Cheng X, Yeo JY, Mandal J, Yang T, Mei X, Saha P, Golonka RM, Yeoh BS. et al. Conjugated bile acids are nutritionally re-programmable antihypertensive metabolites. J Hypertens. 2023;41(6):979–994. doi:10.1097/HJH.0000000000003423.
   PubMed Web of Science ®Google Scholar
• Li C, Yang J, Wang Y, Qi Y, Yang W, Li Y. Farnesoid X receptor agonists as therapeutic target for cardiometabolic diseases. Front Pharmacol. 2020;11:1247. doi:10.3389/fphar.2020.01247.
   PubMed Web of Science ®Google Scholar
• Yang ZH, Liu F, Zhu XR, Suo FY, Jia ZJ, Yao SK. Altered profiles of fecal bile acids correlate with gut microbiota and inflammatory responses in patients with ulcerative colitis. World J Gastroenterol. 2021;27(24):3609–3629. doi:10.3748/wjg.v27.i24.3609.
   PubMed Web of Science ®Google Scholar
• Tomasova L, Dobrowolski L, Jurkowska H, Wróbel M, Huc T, Ondrias K, Ostaszewski R, Ufnal M. Intracolonic hydrogen sulfide lowers blood pressure in rats. Nitric Oxide. 2016;60:50–58. doi:10.1016/j.niox.2016.09.007.
   PubMed Web of Science ®Google Scholar
• Donertas Ayaz B, Oliveira AC, Malphurs WL, Redler T, de Araujo AM, Sharma RK, Sirmagul B, Zubcevic J. Central administration of hydrogen sulfide donor NaHS reduces Iba1-positive cells in the PVN and attenuates rodent angiotensin ii hypertension. Front Neurosci. 2021;15:690919. doi:10.3389/fnins.2021.690919.
   PubMed Web of Science ®Google Scholar
• Xiao L, Dong JH, Teng X, Jin S, Xue HM, Liu SY, Guo Q, Shen W, Ni XC, Wu YM. Hydrogen sulfide improves endothelial dysfunction in hypertension by activating peroxisome proliferator-activated receptor delta/endothelial nitric oxide synthase signaling. J Hypertens. 2018;36(3):651–665. doi:10.1097/HJH.0000000000001605.
   PubMed Web of Science ®Google Scholar
• Weber GJ, Pushpakumar S, Tyagi SC, Sen U. Homocysteine and hydrogen sulfide in epigenetic, metabolic and microbiota related renovascular hypertension. Pharmacol Res. 2016;113:300–312. doi:10.1016/j.phrs.2016.09.002.
   PubMed Web of Science ®Google Scholar
• Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, Nagler CR, Ismagilov RF, Mazmanian SK, Hsiao EY. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015;161(2):264–276. doi:10.1016/j.cell.2015.02.047.
   PubMed Web of Science ®Google Scholar
• Zubcevic J, Richards EM, Yang T, Kim S, Sumners C, Pepine CJ, Raizada MK. Impaired autonomic nervous system-microbiome circuit in hypertension. Circ Res. 2019;125(1):104–116. doi:10.1161/CIRCRESAHA.119.313965.
   PubMed Web of Science ®Google Scholar
• Yang T, Richards EM, Pepine CJ, Raizada MK. The gut microbiota and the brain–gut–kidney axis in hypertension and chronic kidney disease. Nat Rev Nephrol. 2018;14(7):442–456. doi:10.1038/s41581-018-0018-2.
   PubMed Web of Science ®Google Scholar
• Robles-Vera I, Toral M, de la Visitación N, Sánchez M, Gómez-Guzmán M, Romero M, Yang T, Izquierdo-Garcia JL, Jiménez R, Ruiz-Cabello J. et al. Probiotics prevent dysbiosis and the rise in blood pressure in genetic hypertension: role of short-chain fatty acids. Mol Nutr Food Res. 2020;64(6):e1900616. doi:10.1002/mnfr.201900616.
   PubMed Web of Science ®Google Scholar
• He J, Zhang P, Shen L, Niu L, Tan Y, Chen L, Zhao Y, Bai L, Hao X, Li X. et al. Short-chain fatty acids and their association with signalling pathways in inflammation, glucose and lipid metabolism. Int J Mol Sci. 2020;21(17):6356. doi:10.3390/ijms21176356.
   PubMed Web of Science ®Google Scholar
• Chen L, He FJ, Dong Y, Huang Y, Wang C, Harshfield GA, Zhu H. Modest sodium reduction increases circulating short-chain fatty acids in untreated hypertensives: a randomized, double-blind, placebo-controlled trial. Hypertension. 2020;76(1):73–79. doi:10.1161/HYPERTENSIONAHA.120.14800.
   PubMed Web of Science ®Google Scholar
• Yang T, Magee KL, Colon-Perez LM, Larkin R, Liao YS, Balazic E, Cowart JR, Arocha R, Redler T, Febo M. et al. Impaired butyrate absorption in the proximal colon, low serum butyrate and diminished central effects of butyrate on blood pressure in spontaneously hypertensive rats. Acta Physiol (Oxf). 2019;226(2):e13256. doi:10.1111/apha.13256.
   PubMed Web of Science ®Google Scholar
• de la Cuesta-Zuluaga J, Mueller NT, Álvarez-Quintero R, Velásquez-Mejía EP, Sierra JA, Corrales-Agudelo V, Carmona JA, Abad JM, Escobar JS. Higher fecal short-chain fatty acid levels are associated with gut microbiome dysbiosis, obesity, hypertension and cardiometabolic disease risk factors. Nutrients. 2018;11(1):11. doi:10.3390/nu11010051.
   PubMed Web of Science ®Google Scholar
• Calderón-Pérez L, Gosalbes MJ, Yuste S, Valls RM, Pedret A, Llauradó E, Jimenez-Hernandez N, Artacho A, Pla-Pagà L, Companys J. et al. Gut metagenomic and short chain fatty acids signature in hypertension: a cross-sectional study. Sci Rep. 2020;10(1):6436. doi:10.1038/s41598-020-63475-w.
   PubMed Web of Science ®Google Scholar
• Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, Glickman JN, Garrett WS. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341(6145):569–573. doi:10.1126/science.1241165.
   PubMed Web of Science ®Google Scholar
• Natarajan N, Hori D, Flavahan S, Steppan J, Flavahan NA, Berkowitz DE, Pluznick JL. Microbial short chain fatty acid metabolites lower blood pressure via endothelial G protein-coupled receptor 41. Physiol Genomics. 2016;48(11):826–834. doi:10.1152/physiolgenomics.00089.2016.
   PubMed Web of Science ®Google Scholar
• Felizardo RJF, de Almeida DC, Pereira RL, Watanabe IKM, Doimo NTS, Ribeiro WR, Cenedeze MA, Hiyane MI, Amano MT, Braga TT. et al. Gut microbial metabolite butyrate protects against proteinuric kidney disease through epigenetic- and GPR109a-mediated mechanisms. FASEB J. 2019;33(11):11894–11908. doi:10.1096/fj.201901080R.
   PubMed Web of Science ®Google Scholar
• Marques FZ, Nelson E, Chu PY, Horlock D, Fiedler A, Ziemann M, Tan JK, Kuruppu S, Rajapakse NW, El-Osta A. et al. High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice. Circulation. 2017;135(10):964–977. doi:10.1161/CIRCULATIONAHA.116.024545.
   PubMed Web of Science ®Google Scholar
• Ge X, Zheng L, Zhuang R, Yu P, Xu Z, Liu G, Xi X, Zhou X, Fan H. The gut microbial metabolite trimethylamine N-Oxide and hypertension risk: a systematic review and dose–response meta-analysis. Adv Nutr. 2020;11(1):66–76. doi:10.1093/advances/nmz064.
   PubMed Web of Science ®Google Scholar
• Li D, Lu Y, Yuan S, Cai X, He Y, Chen J, Wu Q, He D, Fang A, Bo Y. et al. Gut microbiota–derived metabolite trimethylamine-N-oxide and multiple health outcomes: an umbrella review and updated meta-analysis. Am J Clin Nutr. 2022;116(1):230–243. doi:10.1093/ajcn/nqac074.
   PubMed Web of Science ®Google Scholar
• Liu M, Han Q, Yang J. Trimethylamine-N-oxide (TMAO) increased aquaporin-2 expression in spontaneously hypertensive rats. Clin Exp Hypertens. 2019;41(4):312–322. doi:10.1080/10641963.2018.1481420.
   PubMed Web of Science ®Google Scholar
• Wu WK, Chen CC, Liu PY, Panyod S, Liao BY, Chen PC, Kao HL, Kuo HC, Kuo CH, Chiu THT. et al. Identification of TMAO-producer phenotype and host–diet–gut dysbiosis by carnitine challenge test in human and germ-free mice. Gut. 2019;68(8):1439–1449. doi:10.1136/gutjnl-2018-317155.
   PubMed Web of Science ®Google Scholar
• Chiang JYL, Ferrell JM. Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis. Liver Res. 2020;4(2):47–63. doi:10.1016/j.livres.2020.05.001.
   PubMedGoogle Scholar
• Dopico AM, Walsh JV, Singer JJ. Natural bile acids and synthetic analogues modulate large conductance Ca2±activated K+ (BKCa) channel activity in smooth muscle cells. J Gen Physiol. 2002;119(3):251–273. doi:10.1085/jgp.20028537.
   PubMed Web of Science ®Google Scholar
• Pols TW, Noriega LG, Nomura M, Auwerx J, Schoonjans K. The bile acid membrane receptor TGR5: a valuable metabolic target. Dig Dis. 2011;29(1):37–44. doi:10.1159/000324126.
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Zampella A, Cirino G, Bucci M, Distrutti E. Decoding the vasoregulatory activities of bile acid-activated receptors in systemic and portal circulation: role of gaseous mediators. Am J Physiol Heart Circ Physiol. 2017;312(1):H21–H32. doi:10.1152/ajpheart.00577.2016.
   PubMed Web of Science ®Google Scholar
• Shi H, Zhang B, Abo-Hamzy T, Nelson JW, Ambati CSR, Petrosino JF, Bryan RM, Durgan DJ. Restructuring the gut microbiota by intermittent fasting lowers blood pressure. Circ Res. 2021;128(9):1240–1254. doi:10.1161/CIRCRESAHA.120.318155.
   PubMed Web of Science ®Google Scholar
• Zhang Q, He F, Kuruba R, Gao X, Wilson A, Li J, Billiar TR, Pitt BR, Xie W, Li S. FXR-mediated regulation of angiotensin type 2 receptor expression in vascular smooth muscle cells. Cardiovasc Res. 2008;77(3):560–569. doi:10.1093/cvr/cvm068.
   PubMed Web of Science ®Google Scholar
• Ali Q, Patel S, Hussain T. Angiotensin AT2 receptor agonist prevents salt-sensitive hypertension in obese Zucker rats. Am J Physiol Renal Physiol. 2015;308(12):F1379–1385. doi:10.1152/ajprenal.00002.2015.
   PubMed Web of Science ®Google Scholar
• Renga B, Cipriani S, Carino A, Simonetti M, Zampella A, Fiorucci S, Avila MA. Reversal of endothelial dysfunction by GPBAR1 agonism in portal hypertension involves a AKT/FOXOA1 dependent regulation of H2S generation and endothelin-1. PLOS ONE. 2015;10(11):e0141082. doi:10.1371/journal.pone.0141082.
   PubMed Web of Science ®Google Scholar
• Schwabl P, Hambruch E, Seeland BA, Hayden H, Wagner M, Garnys L, Strobel B, Schubert TL, Riedl F, Mitteregger D. et al. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. J Hepatol. 2017;66(4):724–733. doi:10.1016/j.jhep.2016.12.005.
   PubMed Web of Science ®Google Scholar
• Hine C, Harputlugil E, Zhang Y, Ruckenstuhl C, Lee BC, Brace L, Longchamp A, Treviño-Villarreal JH, Mejia P, Ozaki CK. et al. Endogenous hydrogen sulfide production is essential for dietary restriction benefits. Cell. 2015;160(1–2):132–144. doi:10.1016/j.cell.2014.11.048.
   PubMed Web of Science ®Google Scholar
• Rose P, Moore PK, Whiteman M, Kirk C, Zhu YZ. Diet and hydrogen sulfide production in mammals. Antioxid Redox Signal. 2021;34(17):1378–1393. doi:10.1089/ars.2020.8217.
   PubMed Web of Science ®Google Scholar
• Magee EA, Richardson CJ, Hughes R, Cummings JH. Contribution of dietary protein to sulfide production in the large intestine: an in vitro and a controlled feeding study in humans. Am J Clin Nutr. 2000;72(6):1488–1494. doi:10.1093/ajcn/72.6.1488.
   PubMed Web of Science ®Google Scholar
• Tomasova L, Konopelski P, Ufnal M. Gut bacteria and hydrogen sulfide: The new old players in circulatory system homeostasis. Molecules. 2016;21(11):1558. doi:10.3390/molecules21111558.
   PubMed Web of Science ®Google Scholar
• Szlęzak D, Bronowicka-Adamska P, Hutsch T, Ufnal M, Wróbel M. Hypertension and aging affect liver sulfur metabolism in rats. Cells. 2021;10(5):1238. doi:10.3390/cells10051238.
   PubMed Web of Science ®Google Scholar
• Yang G, Wu L, Jiang B, Yang W, Qi J, Cao K, Meng Q, Mustafa AK, Mu W, Zhang S. et al. H 2 S as a physiologic vasorelaxant: Hypertension in mice with deletion of cystathionine γ-lyase. Science. 2008;322(5901):587–590. doi:10.1126/science.1162667.
   PubMed Web of Science ®Google Scholar
• Huc T, Jurkowska H, Wróbel M, Jaworska K, Onyszkiewicz M, Ufnal M. Colonic hydrogen sulfide produces portal hypertension and systemic hypotension in rats. Exp Biol Med (Maywood). 2018;243(1):96–106. doi:10.1177/1535370217741869.
   PubMed Web of Science ®Google Scholar
• Watts SW, Morrison SF, Davis RP, Barman SM, Daws LC. Serotonin and blood pressure regulation. Pharmacol Rev. 2012;64(2):359–388. doi:10.1124/pr.111.004697.
   PubMed Web of Science ®Google Scholar
• Watts SW, Davis RP. 5-hydroxtryptamine receptors in systemic hypertension: an arterial focus. Cardiovasc Ther. 2011;29(1):54–67. doi:10.1111/j.1755-5922.2010.00173.x.
   PubMed Web of Science ®Google Scholar
• Campbell NRC, Whelton PK, Orias M, Wainford RD, Cappuccio FP, Ide N, Neal B, Cohn J, Cobb LK, Webster J. et al. 2023 world hypertension league, resolve to save lives and international society of hypertension dietary sodium (salt) global call to action. J Hum Hypertens. 2022;37(6):428–437. doi:10.1038/s41371-022-00690-0.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Fahimi S, Singh GM, Micha R, Khatibzadeh S, Engell RE, Lim S, Danaei G, Ezzati M, Powles J. et al. Global sodium consumption and death from cardiovascular causes. N Engl J Med. 2014;371(7):624–634. doi:10.1056/NEJMoa1304127.
   PubMed Web of Science ®Google Scholar
• Charchar FJ, Prestes PR, Mills C, Ching SM, Neupane D, Marques FZ, Sharman JE, Vogt L, Burrell LM, Korostovtseva L. et al. Lifestyle management of hypertension: International society of hypertension position paper endorsed by the world hypertension league and European society of hypertension. J Hypertens. 2024;42(1):23–49. doi:10.1097/HJH.0000000000003563.
   PubMed Web of Science ®Google Scholar
• Miranda PM, De Palma G, Serkis V, Lu J, Louis-Auguste MP, McCarville JL, Verdu EF, Collins SM, Bercik P. High salt diet exacerbates colitis in mice by decreasing lactobacillus levels and butyrate production. Microbiome. 2018;6:57. doi:10.1186/s40168-018-0433-4.
   PubMed Web of Science ®Google Scholar
• Bier A, Braun T, Khasbab R, Di Segni A, Grossman E, Haberman Y, Leibowitz A. A high salt diet modulates the gut microbiota and short chain fatty acids production in a salt-sensitive hypertension rat model. Nutrients. 2018;10(9):1154. doi:10.3390/nu10091154.
   PubMed Web of Science ®Google Scholar
• Ferguson JF, Aden LA, Barbaro NR, Van Beusecum JP, Xiao L, Simmons AJ, Warden C, Pasic L, Himmel LE, Washington MK. et al. High dietary salt–induced DC activation underlies microbial dysbiosis-associated hypertension. JCI Insight. 2019;4(13). doi:10.1172/jci.insight.126241.
   PubMed Web of Science ®Google Scholar
• Wilck N, Matus MG, Kearney SM, Olesen SW, Forslund K, Bartolomaeus H, Haase S, Mähler A, Balogh A, Markó L. et al. Salt-responsive gut commensal modulates T. Nature. 2017;551(7682):585–589. doi:10.1038/nature24628.
   PubMed Web of Science ®Google Scholar
• Norlander AE, Madhur MS. Inflammatory cytokines regulate renal sodium transporters: how, where, and why? Am J Physiol Renal Physiol. 2017;313(2):F141–F144. doi:10.1152/ajprenal.00465.2016.
   PubMed Web of Science ®Google Scholar
• Kang MJ, Kim HG, Kim JS, Oh DG, Um YJ, Seo CS, Han JW, Cho HJ, Kim GH, Jeong TC. et al. The effect of gut microbiota on drug metabolism. Expert Opin Drug Metab Toxicol. 2013;9(10):1295–1308. doi:10.1517/17425255.2013.807798.
   PubMed Web of Science ®Google Scholar
• Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL. Separating host and microbiome contributions to drug pharmacokinetics and toxicity. Science. 2019;363(6427). doi:10.1126/science.aat9931.
   Web of Science ®Google Scholar
• Kyoung J, Atluri RR, Yang T. Resistance to antihypertensive drugs: is gut microbiota the missing link? Hypertension. 2022;79(10):2138–2147. doi:10.1161/HYPERTENSIONAHA.122.19826.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang JW, Li W, Ma H, Sun J, Deng MC, Yang L. Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol Sci. 2006;91(2):356–364. doi:10.1093/toxsci/kfj164.
   PubMed Web of Science ®Google Scholar
• Mruk-Mazurkiewicz H, Kulaszyńska M, Jakubczyk K, Janda-Milczarek K, Czarnecka W, Rębacz-Maron E, Zacha S, Sieńko J, Zeair S, Dalewski B. et al. Clinical relevance of gut microbiota alterations under the influence of selected drugs—updated review. Biomedicines. 2023;11(3):11. doi:10.3390/biomedicines11030952.
   Web of Science ®Google Scholar
• Li Y, Zhao D, Qian M, Liu J, Pan C, Zhang X, Duan X, Zhang Y, Jia W, Wang L. Amlodipine, an anti-hypertensive drug, alleviates non-alcoholic fatty liver disease by modulating gut microbiota. Br J Pharmacol. 2022;179(9):2054–2077. doi:10.1111/bph.15768.
   PubMed Web of Science ®Google Scholar
• Haiser HJ, Gootenberg DB, Chatman K, Sirasani G, Balskus EP, Turnbaugh PJ. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science. 2013;341(6143):295–298. doi:10.1126/science.1235872.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Wang F, Li Q, Zhu M, Du A, Tang W, Chen W. Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation. Drug Metab Dispos. 2014;42(2):245–249. doi:10.1124/dmd.113.055400.
   PubMed Web of Science ®Google Scholar
• Yoo HH, Kim IS, Yoo DH, Kim DH. Effects of orally administered antibiotics on the bioavailability of amlodipine: gut microbiota-mediated drug interaction. J Hypertens. 2016;34(1):156–162. doi:10.1097/HJH.0000000000000773.
   PubMed Web of Science ®Google Scholar
• Santisteban MM, Qi Y, Zubcevic J, Kim S, Yang T, Shenoy V, Cole-Jeffrey CT, Lobaton GO, Stewart DC, Rubiano A. et al. Hypertension-linked pathophysiological alterations in the gut. Circ Res. 2017;120(2):312–323. doi:10.1161/CIRCRESAHA.116.309006.
   PubMed Web of Science ®Google Scholar
• Jaworska K, Huc T, Samborowska E, Dobrowolski L, Bielinska K, Gawlak M, Ufnal M, Chamaillard M. Hypertension in rats is associated with an increased permeability of the colon to TMA, a gut bacteria metabolite. PLOS ONE. 2017;12(12):e0189310. doi:10.1371/journal.pone.0189310.
   PubMed Web of Science ®Google Scholar
• Konop M, Radkowski M, Grochowska M, Perlejewski K, Samborowska E, Ufnal M. Enalapril decreases rat plasma concentration of TMAO, a gut bacteria-derived cardiovascular marker. Biomarkers. 2018;23(4):380–385. doi:10.1080/1354750X.2018.1432689.
   PubMed Web of Science ®Google Scholar
• Yang T, Aquino V, Lobaton GO, Li H, Colon-Perez L, Goel R, Qi Y, Zubcevic J, Febo M, Richards EM. et al. Sustained captopril-induced reduction in blood pressure is associated with alterations in gut-brain axis in the spontaneously hypertensive rat. J Am Heart Assoc. 2019;8(4):e010721. doi:10.1161/JAHA.118.010721.
   PubMed Web of Science ®Google Scholar
• Li HB, Yang T, Richards EM, Pepine CJ, Raizada MK. Maternal treatment with captopril persistently alters gut-brain communication and attenuates hypertension of male offspring. Hypertension. 2020;75(5):1315–1324. doi:10.1161/HYPERTENSIONAHA.120.14736.
   PubMed Web of Science ®Google Scholar
• Kyoung J, Yang T. Depletion of the gut microbiota enhances the blood pressure-lowering effect of captopril: implication of the gut microbiota in resistant hypertension. Hypertens Res. 2022;45(9):1505–1510. doi:10.1038/s41440-022-00921-4.
   PubMed Web of Science ®Google Scholar
• Yang T, Mei X, Tackie-Yarboi E, Akere MT, Kyoung J, Mell B, Yeo JY, Cheng X, Zubcevic J, Richards EM. et al. Identification of a gut commensal that compromises the blood pressure-lowering effect of ester angiotensin-converting enzyme inhibitors. Hypertension. 2022;79(8):1591–1601. doi:10.1161/HYPERTENSIONAHA.121.18711.
   PubMed Web of Science ®Google Scholar
• Robles-Vera I, Toral M, de la Visitación N, Sánchez M, Gómez-Guzmán M, Muñoz R, Algieri F, Vezza T, Jiménez R, Gálvez J. et al. Changes to the gut microbiota induced by losartan contributes to its antihypertensive effects. Br J Pharmacol. 2020;177(9):2006–2023. doi:10.1111/bph.14965.
   PubMed Web of Science ®Google Scholar
• Dong S, Liu Q, Zhou X, Zhao Y, Yang K, Li L, Zhu D. Effects of losartan, atorvastatin, and aspirin on blood pressure and gut microbiota in spontaneously hypertensive rats. Molecules. 2023;28(2):28. doi:10.3390/molecules28020612.
   Web of Science ®Google Scholar
• Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019;570(7762):462–467. doi:10.1038/s41586-019-1291-3.
   PubMed Web of Science ®Google Scholar
• González-Correa C, Moleón J, Miñano S, Robles-Vera I, Toral M, Martín-Morales N, O’Valle F, Sánchez M, Gómez-Guzmán M, Jiménez R. et al. Mineralocorticoid receptor blockade improved gut microbiota dysbiosis by reducing gut sympathetic tone in spontaneously hypertensive rats. Biomed Pharmacother. 2023;158:114149. doi:10.1016/j.biopha.2022.114149.
   PubMed Web of Science ®Google Scholar
• Kaur S, Bhattacharyya R, Banerjee D. Hydrochlorothiazide and indapamide bind the NADPH binding site of bacterial dihydrofolate reductase: results of an in-silico study and their implications. Silico Pharmacol. 2020;8(1):5. doi:10.1007/s40203-020-00056-9.
   PubMedGoogle Scholar
• Brocker CN, Velenosi T, Flaten HK, McWilliams G, McDaniel K, Shelton SK, Saben J, Krausz KW, Gonzalez FJ, Monte AA. Metabolomic profiling of metoprolol hypertension treatment reveals altered gut microbiota-derived urinary metabolites. Hum Genomics. 2020;14:10. doi:10.1186/s40246-020-00260-w.
   PubMed Web of Science ®Google Scholar
• Zhernakova A, Kurilshikov A, Bonder MJ, Tigchelaar EF, Schirmer M, Vatanen T, Mujagic Z, Vila AV, Falony G, Vieira-Silva S. et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science. 2016;352(6285):565–569. doi:10.1126/science.aad3369.
   PubMed Web of Science ®Google Scholar
• Lim YL, Kim MY, Jang YO, Baik SK, Kwon SO. Rifaximin and propranolol combination therapy is more effective than propranolol monotherapy for the reduction of portal pressure: an open randomized controlled pilot study. Gut Liver. 2017;11(5):702–710. doi:10.5009/gnl16478.
   PubMed Web of Science ®Google Scholar
• Honour J. The possible involvement of intestinal bacteria in steroidal hypertension. Endocrinology. 1982;110(1):285–287. doi:10.1210/endo-110-1-285.
   PubMed Web of Science ®Google Scholar
• Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, Zadeh M, Gong M, Qi Y, Zubcevic J. et al. Gut dysbiosis is linked to hypertension. Hypertension. 2015;65(6):1331–1340. doi:10.1161/hypertensionaha.115.05315.
   PubMed Web of Science ®Google Scholar
• Galla S, Chakraborty S, Cheng X, Yeo JY, Mell B, Chiu N, Wenceslau CF, Vijay-Kumar M, Joe B. Exposure to amoxicillin in early life is associated with changes in gut microbiota and reduction in blood pressure: findings from a study on rat dams and offspring. J Am Heart Assoc. 2020;9(2):e014373. doi:10.1161/JAHA.119.014373.
   PubMed Web of Science ®Google Scholar
• Hsu CN, Chan JYH, Klh W, Yu HR, Lee WC, Hou CY, Tain YL. Altered gut microbiota and its metabolites in hypertension of developmental origins: exploring differences between fructose and antibiotics exposure. Int J Mol Sci. 2021;22(5):22. doi:10.3390/ijms22052674.
   Web of Science ®Google Scholar
• Galla S, Chakraborty S, Cheng X, Yeo J, Mell B, Zhang H, Mathew AV, Vijay-Kumar M, Joe B. Disparate effects of antibiotics on hypertension. Physiol Genomics. 2018;50(10):837–845. doi:10.1152/physiolgenomics.00073.2018.
   PubMed Web of Science ®Google Scholar
• Lewis-Mikhael AM, Davoodvandi A, Jafarnejad S. Effect of Lactobacillus plantarum containing probiotics on blood pressure: A systematic review and meta-analysis. Pharmacol Res. 2020;153:104663. doi:10.1016/j.phrs.2020.104663.
   PubMed Web of Science ®Google Scholar
• Qi D, Nie XL, Zhang JJ. The effect of probiotics supplementation on blood pressure: a systemic review and meta-analysis. Lipids Health Dis. 2020;19(1):79. doi:10.1186/s12944-020-01259-x.
   PubMed Web of Science ®Google Scholar
• Zarezadeh M, Musazadeh V, Ghalichi F, Kavyani Z, Nasernia R, Parang M, Jamilian P, Fakhr L, Ostadrahimi A, Mekary RA. Effects of probiotics supplementation on blood pressure: An umbrella meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2023;33(2):275–286. doi:10.1016/j.numecd.2022.09.005.
   PubMed Web of Science ®Google Scholar
• Kong CY, Li ZM, Mao YQ, Chen HL, Hu W, Han B, Wang LS. Probiotic yogurt blunts the increase of blood pressure in spontaneously hypertensive rats via remodeling of the gut microbiota. Food Funct. 2021;12(20):9773–9783. doi:10.1039/d1fo01836a.
   PubMed Web of Science ®Google Scholar
• Gómez-Guzmán M, Toral M, Romero M, Jiménez R, Galindo P, Sánchez M, Zarzuelo MJ, Olivares M, Gálvez J, Duarte J. Antihypertensive effects of probiotics Lactobacillus strains in spontaneously hypertensive rats. Mol Nutr Food Res. 2015;59(11):2326–2336. doi:10.1002/mnfr.201500290.
   PubMed Web of Science ®Google Scholar
• Grylls A, Seidler K, Neil J. Link between microbiota and hypertension: Focus on LPS/TLR4 pathway in endothelial dysfunction and vascular inflammation, and therapeutic implication of probiotics. Biomed Pharmacother. 2021;137:111334. doi:10.1016/j.biopha.2021.111334.
   PubMed Web of Science ®Google Scholar
• Toral M, Romero M, Rodríguez-Nogales A, Jiménez R, Robles-Vera I, Algieri F, Chueca-Porcuna N, Sánchez M, de la Visitación N, Olivares M. et al. Lactobacillus fermentum improves tacrolimus-induced hypertension by restoring vascular redox state and improving eNOS coupling. Mol Nutr Food Res. 2018;62(14):e1800033. doi:10.1002/mnfr.201800033.
   PubMed Web of Science ®Google Scholar
• Xue Y, Cui L, Qi J, Ojo O, Du X, Liu Y, Wang X. The effect of dietary fiber (oat bran) supplement on blood pressure in patients with essential hypertension: A randomized controlled trial. Nutr Metab Cardiovasc Dis. 2021;31(8):2458–2470. doi:10.1016/j.numecd.2021.04.013.
   PubMed Web of Science ®Google Scholar
• Gut microbial metabolites lower blood pressure in patients with hypertension. Nat Cardiovasc Res. 2023;2(1):18–19. doi:10.1038/s44161-022-00204-8.
   PubMedGoogle Scholar
• Almeida C, Oliveira R, Baylina P, Fernandes R, Teixeira FG, Barata P. Current trends and challenges of fecal microbiota transplantation—an easy method that works for all? Biomedicines. 2022;10(11):2742. doi:10.3390/biomedicines10112742.
   PubMed Web of Science ®Google Scholar
• Zhang T, Lu G, Zhao Z, Liu Y, Shen Q, Li P, Chen Y, Yin H, Wang H, Marcella C. et al. Washed microbiota transplantation vs. manual fecal microbiota transplantation: clinical findings, animal studies and in vitro screening. Protein Cell. 2020;11(4):251–266. doi:10.1007/s13238-019-00684-8.
   PubMed Web of Science ®Google Scholar
• Zhong HJ, Zeng HL, Cai YL, Zhuang YP, Liou YL, Wu Q, He XX. Washed microbiota transplantation lowers blood pressure in patients with hypertension. Front Cell Infect Microbiol. 2021;11:679624. doi:10.3389/fcimb.2021.679624.
   PubMed Web of Science ®Google Scholar
• Ramos-Pollán R, Guevara-López MA, Suárez-Ortega C, Díaz-Herrero G, Franco-Valiente JM, Rubio-Del-Solar M, González-de-Posada N, Vaz MA, Loureiro J, Ramos I. Discovering mammography-based machine learning classifiers for breast cancer diagnosis. J Med Syst. 2012;36(4):2259–2269. doi:10.1007/s10916-011-9693-2.
   PubMed Web of Science ®Google Scholar
• Barberio B, Facchin S, Patuzzi I, Ford AC, Massimi D, Valle G, Sattin E, Simionati B, Bertazzo E, Zingone F. et al. A specific microbiota signature is associated to various degrees of ulcerative colitis as assessed by a machine learning approach. Gut Microbes. 2022;14(1):2028366. doi:10.1080/19490976.2022.2028366.
   PubMed Web of Science ®Google Scholar
• Islam SMS, Talukder A, Awal MA, Siddiqui MMU, Ahamad MM, Ahammed B, Rawal LB, Alizadehsani R, Abawajy J, Laranjo L. et al. Machine learning approaches for predicting hypertension and its associated factors using population-level data from three South Asian countries. Front Cardiovasc Med. 2022;9:839379. doi:10.3389/fcvm.2022.839379.
   PubMed Web of Science ®Google Scholar
• Aryal S, Alimadadi A, Manandhar I, Joe B, Cheng X. Machine learning strategy for gut microbiome-based diagnostic screening of cardiovascular disease. Hypertension. 2020;76(5):1555–1562. doi:10.1161/HYPERTENSIONAHA.120.15885.
   PubMed Web of Science ®Google Scholar
• Mirzayi C, Renson A, Zohra F, Elsafoury S, Geistlinger L, Kasselman LJ, Eckenrode K, van de Wijgert J, Loughman A, Marques FZ. et al. Reporting guidelines for human microbiome research: the STORMS checklist. Nat Med. 2021;27(11):1885–1892. doi:10.1038/s41591-021-01552-x.
   PubMed Web of Science ®Google Scholar
• Gutierrez Lopez DE, Lashinger LM, Weinstock GM, Bray MS. Circadian rhythms and the gut microbiome synchronize the host’s metabolic response to diet. Cell Metab. 2021;33(5):873–887. doi:10.1016/j.cmet.2021.03.015.
   PubMed Web of Science ®Google Scholar
• Bardhan P, Yang T. Sexual dimorphic interplays between gut microbiota and antihypertensive drugs. Curr Hypertens Rep. 2023;25(8):163–172. doi:10.1007/s11906-023-01244-6.
   PubMed Web of Science ®Google Scholar